Research Article
Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study
Table 2
Characteristics of patients with liver cirrhosis and noncirrhotic CLD during COVID-19 and during hospitalization.
| | Variables | Cirrhosis () ( (%)) | Noncirrhotic CLD () ( (%)) | value |
| | Female | 20 (31.3) | 102 (51.8) | 0.004 | | Age (years), mean (SD) | 66.66 (11.1) | 52.71 (15.6) | <0.001 | | Charlson Comorbidity Index, mean (SD) | 5.4 (1.8) | 2.6 (2.3) | <0.001 | | Hospitalization due to COVID-19 | 32 (50) | 46 (23) | <0.001 | | Admitted to intensive care unit | 7 (10.9) | 5 (2.5) | 0.005 | | Mechanical ventilation | 5 (7.8) | 5 (2.5) | 0.066 | | Noninvasive ventilation | 3 (4.7) | 0 (0) | 0.01 | | Hospitalization length (days), mediana (IQR) | 12.5 (19) | 6 (16) | 0.04 | | COVID-19-specific therapy in hospitalized patients | | | | | Oxygen | 24 (37.5) | 27 (13.5) | <0.001 | | Piperacillin/tazobactam | 20 (31.3) | 19 (9.5) | <0.001 | | Tinzaparin | 19 (29.7) | 22 (11) | <0.001 | | Central vein catheter | 13 (20.3) | 2 (1) | <0.001 | | Corticosteroids | 12 (18.8) | 18 (9) | 0.032 | | Continuous positive airway pressure | 11 (17.2) | 6 (3) | <0.001 | | Remdesivir | 9 (14.1) | 12 (6) | 0.038 | | Penicillin | 2 (3.1) | 7 (3.5) | 0.886 | | Chest X-ray | | | | | Normal | 9 (28.1) | 8 (17.4) | 0.259 | | Ground-glass opacities | 4 (12.5) | 6 (13.0) | 1 | | Pneumonia | 15 (46.9) | 20 (43.5) | 0.767 | | Pleural effusions | 5 (15.6) | 2 (4.3) | 0.116 | | Pulmonary edema | 4 (12.5) | 1 (2.2) | 0.153 | | Pneumothorax | 2 (6.3) | 0 | 0.165 | | Bacterial infectionb | 21 (65.6) | 32 (69.6) | 0.714 | | Outcome of hospitalization | | | | | Own home without help | 12 (37.5) | 35 (76.1) | | | Own home with help | 2 (6.3) | 2 (4.3) | | | Rehabilitation centers | 5 (15.6) | 5 (10.9) | | | Nursing home | 0 (0) | 1 (2.2) | | | Hospice | 1 (3.1) | 0 (0) | | | Death | 12 (37.4) | 3 (6.5) | 0.001 |
|
|
aMedian. bBacterial pneumonia and/or positive blood culture and/or sepsis.
|
